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Long INterspersed Element-1 (LINE-1 or L1) retrotransposons form the only
autonomously active family of transposable elements in humans. They are expressed
and mobile in the germline, in embryonic stem cells and in the early embryo, but are
silenced in most somatic tissues. Consistently, they play an important role in individual
genome variations through insertional mutagenesis and sequence transduction, which
occasionally lead to novel genetic diseases. In addition, they are reactivated in nearly
half of the human epithelial cancers, contributing to tumor genome dynamics. The L1
element codes for two proteins, ORF1p and ORF2p, which are essential for its mobility.
ORF1p is an RNA-binding protein with nucleic acid chaperone activity and ORF2p
possesses endonuclease and reverse transcriptase activities. These proteins and the L1
RNA assemble into a ribonucleoprotein particle (L1 RNP), considered as the core of the
retrotransposition machinery. The L1 RNPmediates the synthesis of new L1 copies upon
cleavage of the target DNA and reverse transcription of the L1 RNA at the target site. The
L1 element takes benefit of cellular host factors to complete its life cycle, however several
cellular pathways also limit the cellular accumulation of L1 RNPs and their deleterious
activities. Here, we review the known cellular host factors and pathways that regulate
positively or negatively L1 retrotransposition at post-transcriptional level, in particular by
interacting with the L1machinery or L1 replication intermediates; and how they contribute
to control L1 activity in somatic cells.
Keywords: LINE-1, retrotransposon, genome evolution, repeated sequences, retrotransposition, structural
variation (SV)
L1 ELEMENTS CONTRIBUTE TO THE DYNAMICS OF SOMATIC
AND GERMLINE HUMAN GENOMES
The Long INterspersed Element-1 (LINE-1 or L1) retrotransposon forms 17% of our genome
(Lander et al., 2001). Most L1 copies present in the reference human genome are defective but∼100
copies could be retrotransposition-competent (Brouha et al., 2003). In addition, many polymorphic
L1 elements, not included in the reference genome, also have the potential to mobilize (Beck et al.,
2010; Ewing, 2015; Mir et al., 2015).
L1 elements can retrotranspose in the germline, in embryonic stem cells and in the early
embryo (Kazazian et al., 1988; Garcia-Perez et al., 2007; van den Hurk et al., 2007). However, L1
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retrotransposons are repressed in most tested normal somatic
cells except in the brain (Coufal et al., 2009; Baillie et al.,
2011; Evrony et al., 2012; Richardson et al., 2014b; Upton
et al., 2015). L1 mobilization impacts human genome evolution
through insertional mutagenesis and sequence transduction,
which occasionally results in inherited genetic diseases (Hancks
and Kazazian, 2012). Somatic retrotransposition in the brain
could also contribute to the etiology of some mental disorders
or disabilities, such as Rett Syndrome or Ataxia Telangiectasia,
characterized by increased levels of L1mobilization (Muotri et al.,
2010; Coufal et al., 2011). Moreover, somatic L1 mobilization
participates to the dynamics of many tumor genomes and can
lead to driver mutations (Miki et al., 1992; Iskow et al., 2010;
Lee et al., 2012; Solyom et al., 2012; Shukla et al., 2013; Helman
et al., 2014; Tubio et al., 2014; Doucet-O’Hare et al., 2015;
Ewing et al., 2015; Rodic´ et al., 2015). Besides its impact as an
insertional mutagen, L1 also triggers other forms of genomic
alterations such as DNA double-strand breaks or chromosomal
translocations, and these activities could participate to normal
aging or tumorigenesis (Wallace et al., 2008; Lin et al., 2009;
Belancio et al., 2010). Finally, the L1 machinery also drives the
retrotransposition of Short INterspersed Elements (SINEs) and
the formation of processed pseudogenes (Esnault et al., 2000;
Dewannieux et al., 2003).
L1 elements and their host have co-evolved: L1s use
the cellular machinery for their own replication, while the
host cell has evolved multiple defense mechanisms limiting
FIGURE 1 | L1 retrotransposition and cellular regulators. L1 replication starts with L1 transcription into a full length bicistronic L1 mRNA, its translation into
ORF1p and ORF2p, and the assembly of an L1 RNP. For the sake of simplicity, the recently described antisense ORF0 in the 5′ UTR is not depicted (Denli et al.,
2015). The L1 RNP accumulates in stress granules and at least a fraction of it is imported to the nucleus (not shown) where target-primed reverse transcription (TPRT)
occurs at the target DNA site. Finally, L1 insertion is resolved by an unknown mechanism (see main text for details). Only L1 regulators with a defined
target/mechanism are depicted. Small broken arrows, L1 sense and antisense promoter activities; lollipop, L1 polyadenylation signal; light and dark blue arrowheads,
target sites of L1 progenitor and progeny copies, respectively; red bars, negative regulation; green arrows, positive regulation. TSD, target site duplication;
UTR, untranslated region; RNP, ribonucleoprotein particle; ISG, interferon-responsive genes; RNAi, RNA interference.
L1 deleterious effects. Silencing L1 expression, through CpG
DNA methylation and histone modifications is a major
repressive mechanism, which prevents the accumulation of
mutagenic events (Bourc’His and Bestor, 2004; Castro-Diaz
et al., 2014; Jacobs et al., 2014). Here we review post-
transcriptional cellular pathways, which regulate positively or
negatively L1 retrotransposition in somatic cells, in particular
by interacting with the L1 machinery or L1 replicative
intermediates.
L1 REPLICATION IS MEDIATED BY A
RIBONUCLEOPROTEIN PARTICLE (RNP)
AND TARGET-PRIMED REVERSE
TRANSCRIPTION (TPRT)
An active L1 retrotransposon comprises a 5′ untranslated region
(UTR), two open reading frames (ORF1 and ORF2) separated by
a short inter-ORF spacer and a 3′ UTR (Figure 1). An antisense
ORF0 of unknown function has also been recently described
in the 5′ UTR (Denli et al., 2015). As a consequence of the
reverse transcription and integration mechanism, L1 sequence
ends with a poly(dA) stretch and is flanked by target site
duplications (TSD) of variable size. The 5′ UTR contains RNA
polymerase II sense and antisense promoters (Swergold, 1990;
Speek, 2001; Nigumann et al., 2002). The translation of the
bicistronic L1mRNAby an unconventionalmechanism produces
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two proteins, named ORF1p and ORF2p (Alisch et al., 2006;
Dmitriev et al., 2007). ORF1p is a 40 kDa RNA-binding protein,
forming trimers andwith nucleic acid chaperone activity (Martin,
1991; Holmes et al., 1992; Martin and Bushman, 2001; Martin
et al., 2003; Khazina et al., 2011). ORF2p is a ∼150 kDa protein
with endonuclease (EN) and reverse transcriptase (RT) activities,
which are critical for L1 retrotransposition (Mathias et al., 1991;
Feng et al., 1996; Moran et al., 1996). ORF2p also contains a
C-terminal cysteine-rich region, potentially contributing to its
RNA binding capability (Piskareva et al., 2013). ORF1p and
ORF2p bind the L1 mRNA to form a ribonucleoprotein particle
(RNP), considered as the core of the L1 replicative complex
(Hohjoh and Singer, 1996; Kolosha and Martin, 1997; Kulpa and
Moran, 2005, 2006; Doucet et al., 2010; Goodier et al., 2010).
This assembly occurs preferentially in cis (Esnault et al., 2000;
Wei et al., 2001; Kulpa and Moran, 2006), through binding of
ORF2p to the L1 RNA poly(A) sequence (Doucet et al., 2015). L1
RNPs accumulate in cytoplasmic foci, which colocalize with stress
granules (Goodier et al., 2007, 2010; Doucet et al., 2010). The
functional importance of these cytoplasmic complexes remains
to be elucidated. Although cell division seems to promote
retrotransposition, it is not absolutely required (Kubo et al., 2006;
Shi et al., 2007; Xie et al., 2013). Thus, access of L1 RNPs to
chromatin can occur independently of mitotic nuclear envelope
breakdown through an unknown nuclear import mechanism.
New L1 copies are directly synthesized and inserted in the
genome by a process called TPRT (Luan et al., 1993; Feng
et al., 1996; Cost et al., 2002; Christensen et al., 2006). During
TPRT, ORF2p binds and nicks a consensus sequence of the
form 5′-TTTT/A-3′ in the genomic DNA (Feng et al., 1996).
This cleavage, potentially followed by additional processing
steps, exposes a single-stranded T-rich DNA stretch able to
partially or completely anneal to the L1 RNA poly(A) tail and
to prime ORF2p-mediated reverse transcription (Kulpa and
Moran, 2006; Monot et al., 2013; Viollet et al., 2014). A possible
second nick, generally few nucleotides downstream of the first
one, allows priming and synthesis of the second DNA strand.
Finally, the L1 DNA ends are filled in and sealed, creating TSD
(Luan et al., 1993; Feng et al., 1996; Cost et al., 2002). The
molecular actors involved in these late stages are unknown.
This process is frequently abortive, resulting in 5′ truncated L1
copies.
L1 RETROTRANSPOSITION IS
REGULATED BY CELLULAR FACTORS AT
MULTIPLE LEVELS
L1 activity is regulated at multiple stages of the L1
retrotransposition cycle (Figure 1). We focus here on post-
transcriptional mechanisms and their molecular effectors acting
in human or mammalian somatic cells and interacting with
components of the L1 RNP or with L1 replication intermediates.
L1 regulation in the germline, notably by Piwi-interacting RNA
(piRNA), has been reviewed elsewhere (Zamudio and Bourc’his,
2010; Crichton et al., 2014) and is not detailed in the present
article.
Proteomic Studies Have Revealed Cellular
Partners of L1 RNPs and Potential Novel
Regulators of L1 Retrotransposition
Overview
Several recent studies have identified cellular partners of
L1 RNPs through tagging of ORF1p, ORF2p or L1 RNA,
followed by affinity chromatography and mass-spectrometry
(Goodier et al., 2013; Peddigari et al., 2013; Taylor et al.,
2013; Moldovan and Moran, 2015). These experimental efforts
differ by the cell line, the L1 clone, the tagged component
in the complex and the chromatography method used,
but eventually lead to a number of common host factors
(Figure 2). It should be underlined that only a fraction of
the hits has been validated by co-immunoprecipitation, and
only a single study used quantitative mass-spectrometry to
measure the specific enrichment of the detected proteins upon
elution (Taylor et al., 2013). A first step toward functional
characterization generally involves retrotransposition assays
in cultured cells upon depletion or overexpression of the
tested factor. The outcome of these genetic assays allows a first
classification into positive or negative regulators. However,
many binding partners only modestly impact the levels of L1
retrotransposition in these assays, or have pleiotropic effects
preventing unambiguous interpretation. With few exceptions,
the majority of the tested factors are RNA-binding proteins,
which copurify with ORF1p through an indirect RNA bridge,
colocalize with L1 RNPs in stress granules, and inhibit L1
retrotransposition.
Limitations
Due to the scarcity of L1 endogenous complexes in cells, all
proteomic studies rely on the overexpression of engineered L1
constructs. It is conceivable that: (i) some of the discovered
partners become associated with L1 components as a result
of L1 overexpression beyond physiological levels. (ii) L1 RNP
stoichiometry is altered; (iii) the retrotransposition reporter
cassette, which contains an intron, modifies L1 RNA cellular
processing, and thus its binding partners.
Positive Regulators of
L1 Retrotransposition
Poly(A) Binding Proteins Act in L1 RNP Assembly or
Trafficking
Poly(A) binding proteins (PABPs) bind mRNA poly(A) tails and
are involved in mRNA stability and translation initiation (Goss
and Kleiman, 2013). Short hairpin RNA (shRNA)-mediated
knockdown of PABPC1, reduces L1 retrotransposition with
minimal effects on L1 RNA and proteins accumulation, or
poly(A) tail length (Dai et al., 2012). This effect is associated
with reduced L1 RNP levels and reduced nuclear accumulation
of this complex, suggesting a possible—direct or indirect—role
of PABPC1 in the assembly or the subcellular trafficking of the
L1 RNP. Consistently, PABPC1 associates with the L1 RNP in
an RNA-dependent manner, they colocalize in stress granules
(Goodier et al., 2013; Taylor et al., 2013), and moderate PABPC1
overexpression stimulates retrotransposition (Dai et al., 2012).
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FIGURE 2 | Cellular L1 interactors discovered in recent proteomic studies. The Venn diagram displays the overlap between three major proteomic studies
designed to identify L1 cellular partners (Goodier et al., 2013; Taylor et al., 2013; Moldovan and Moran, 2015). For the sake of simplicity, the overlap with a more
limited fourth study is not shown, but includes NCL and HNRNPL (Peddigari et al., 2013). For hits found in a single study, only those confirmed by
coimmunoprecipitation (coIP) or by quantitative mass-spectrometry are depicted. Bold, confirmed by coIP; red and green, L1 negative and positive regulators,
respectively; white, potential dual role: UPF1 knockdown decreases overall L1 retrotransposition but increases L1 RNA levels, suggesting that it could act at several
stages with opposing effects (Taylor et al., 2013). Upf1 overexpression is not impacting retrotransposition (Moldovan and Moran, 2015).
Other PABPs have been found to associate with the L1 RNA
(PABPN1, PABPC4) but addressing their specific role in L1
retrotransposition has been hampered by pleiotropic effects, or
not yet tested (Dai et al., 2012; Goodier et al., 2013; Taylor et al.,
2013).
PCNA is a Cofactor of TPRT
PCNA is a DNA sliding clamp acting as a processivity factor
for many DNA polymerases during DNA replication or DNA
damage repair (Moldovan et al., 2007). ORF2p binds PCNA
through a PCNA-interacting protein (PIP) box, located between
the EN and RT domains of ORF2p (Taylor et al., 2013).Mutations
in ORF2p PIP box disrupt PCNA-ORF2p interaction and
inhibit L1 retrotransposition. Interestingly, ORF2p mutations
abrogating its EN or RT activity also disrupt PCNA-ORF2p
interaction, suggesting that PCNA binding to ORF2p occurs
downstream or concomitantly with TPRT.
Proline-Directed Protein Kinase(s) Regulate(s) ORF1p
Function
ORF1p contains several (S/T)-P putative phosphorylation
sites for proline-directed protein kinases (PDPKs), such as
mitogen-activated protein kinases and cyclin-dependent kinases.
Mutations of S18, S27, T203, and T213, which are potential
PDPK targets, decrease L1 retrotransposition; and these residues
were found phosphorylated by mass-spectrometry in human
cells (Cook et al., 2015). Interestingly, several protein kinases
associate with the L1 RNP (Goodier et al., 2013; Taylor et al.,
2013; Moldovan and Moran, 2015), however it remains to be
demonstrated if one or several of them might directly target
ORF1p. Interestingly, S18/S27 sites in ORF1p are required
for binding by Pin1 prolyl isomerase (Cook et al., 2015),
suggesting a scenario in which binding of Pin1 promotes ORF1p
conformational change, which could affect its stability, activity
or localization, or its subsequent ability to be dephosphorylated
(Yeh et al., 2004; Liou et al., 2011).
Cellular Pathways Inhibiting L1
Retrotransposition at Post-Transcriptional
Level
RNA Interference Pathways Prevent the
Accumulation of L1 RNA
L1 RNA serves both as an mRNA to produce the L1 machinery
and as a template for reverse transcription. Multiple RNA
interference (RNAi) pathways act in somatic or embryonic
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cells to prevent the accumulation of L1 RNA, and eventually
retrotransposition.
First, the Microprocessor complex (Drosha/DGCR8), a
major nuclear complex implicated in microRNA (miRNA)
biosynthesis through pri-miRNA processing, is also able to bind
L1 RNA in vivo, to reduce its abundance and to limit L1
retrotransposition. In addition, it can cleave various L1 RNA
fragments derived from the L1 5′ UTR region in vitro, indicating
that L1 RNA can be a direct Microprocessor substrate (Heras
et al., 2013, 2014). Moreover, the miRNA pathway could also
act downstream of Microprocessor to inhibit retrotransposition.
Indeed, miR-128 in complex with the Argonaute (Ago) protein
binds the L1 RNA in the ORF2 region leading to L1 transcript
degradation (Hamdorf et al., 2015).
Second, the combined expression of sense and antisense
L1 transcripts driven by L1 5′ UTR promoters reduces L1
RNA stability and L1 retrotransposition (Yang and Kazazian,
2006). This process is associated with the synthesis of rasiRNA
(repeat-associated small interfering RNA) consistent with a
possible processing of L1 RNA duplexes, and is modestly
inhibited by Dicer knockdown, suggesting an additional layer
of L1 repression mediated by siRNA mechanisms. In agreement
with a role of RNAi pathways in somatic L1 regulation, L1 RNPs
tend to accumulate in stress granules where they colocalize with
several RNAi factors and often interact with them (Goodier et al.,
2007, 2013).
Innate Immunity and Interferon Response Pathways
The cellular innate immune response is one of the first
lines of defense against a broad range of viral infections. It
involves cellular factors with antiviral activities, among which
the interferon (IFN) response pathway plays a central role
(MacMicking, 2012; Ivashkiv and Donlin, 2014). This pathway
leads to the activation of IFN-stimulated genes (ISG) acting
as effectors and reinforcing IFN-signaling itself. A significant
proportion of ISG are viral restriction factors (MacMicking,
2012), which also appear to counteract L1 retrotransposition
(Goodier et al., 2015), and are described below.
Upon overexpression, several members of the APOBEC3
(A3) cytidine deaminase family inhibit L1 retrotransposition
(A3A, A3B, A3C and A3F) (Bogerd et al., 2006; Chen et al.,
2006; Muckenfuss et al., 2006; Stenglein and Harris, 2006;
Kinomoto et al., 2007; Niewiadomska et al., 2007). A3A is a
nuclear protein predominantly expressed in peripheral blood
mononuclear cells (PBMCs) and is induced by IFN-β (Chen
et al., 2006; Muckenfuss et al., 2006; Stenglein et al., 2010).
A3A-mediated L1 inhibition depends on A3A deaminase activity
and on the subsequent processing of the deaminated DNA
by uracil DNA glycosylase (UNG) and apurinic/apyrimidinic
endonuclease (APE) (Richardson et al., 2014a). A3B is also a
nuclear protein. It is endogenously expressed in embryonic stem
cells, in induced-pluripotent stem cells and in a number of cancer
cell lines. Its depletion stimulates L1 retrotransposition (Wissing
et al., 2011; Marchetto et al., 2013); however, catalytically
dead A3B mutants still inhibit L1 retrotransposition (Wissing
et al., 2011). Thus, the mechanism by which A3B represses
L1 mobilization remains unknown. Similarly, reducing the
expression of A3C moderately increases retrotransposition in
cancer cell lines that express detectable levels of endogenous A3C
(Muckenfuss et al., 2006). As for A3B, A3C- and A3F-mediated
L1 repression is deaminase-independent (Muckenfuss et al.,
2006; Stenglein and Harris, 2006; Kinomoto et al., 2007; Horn
et al., 2014). A3Cmight interfere with L1 reverse transcription or
the activity of ORF2p in the L1 RNP (Horn et al., 2014).
Several other ISG products, such as MOV10, ZAP or RNase
L, limit L1 replication by limiting L1 RNA accumulation. The
RNA helicase MOV10 robustly copurifies with the L1 complex,
colocalizes with L1 RNPs in stress granules, reduces L1 RNA half-
life, and ultimately strongly inhibits retrotransposition (Arjan-
Odedra et al., 2012; Goodier et al., 2012, 2013; Li et al., 2013;
Taylor et al., 2013; Moldovan and Moran, 2015). Similarly, the
zinc-finger antiviral protein (ZAP) associates with the L1 RNP
and accumulates with it in stress granules (Goodier et al., 2015;
Moldovan and Moran, 2015). Its overexpression reduces full-
length L1 RNA levels, and L1 retrotransposition levels. ZAP
zinc finger domain is necessary and sufficient for its anti-L1
activity. Inversely, knocking down endogenous ZAP increases
L1 retrotransposition. The ribonuclease L (RNase L) degrades
L1 RNA and inhibits retrotransposition although no association
or colocalization was detected with the L1 RNP (Zhang et al.,
2014). Other ISGs with known viral restriction activities (e.g.,
BST2, ISG20, MAVS, and MX2) are also strong inhibitors of L1
retrotransposition (Goodier et al., 2015), but their mechanism of
action has not yet been explored.
Finally, SAMHD1 and TREX1 are ISGs involved in a negative
feedback loop, acting as repressors of the interferon response
itself. Loss-of-function mutations in these genes lead to the
Aicardi-Goutières syndrome, an autoimmune disease. Both
factors inhibit L1 retrotransposition (Stetson et al., 2008; Zhao
et al., 2013). Trex1 (Three-prime-repair exonuclease 1) is an
abundant 3′-5′ DNA exonuclease and its overexpression inhibits
engineered L1 retrotransposition in cultured cells (Stetson et al.,
2008). Trex1-deficient cells accumulate ssDNA fragments derived
from various retroelements including L1, suggesting that Trex1
can metabolize reverse transcribed L1 cDNA (Stetson et al.,
2008). SAMHD1 (SAM Domain And HD Domain 1) impairs
lentivirus replication in non-dividing cells by depleting the
intracellular pool of dNTPs and thereby inhibiting reverse
transcription (Lahouassa et al., 2012). In contrast, SAMHD1
inhibits L1 retrotransposition in dividing cells, through a
dNTPase-independent mechanism, which might directly affect
ORF2p levels, and thus inhibit L1 reverse transcription (Zhao
et al., 2013).
DNA Repair Pathways
EN-mediated cleavage of the target DNA or other TPRT
intermediates could lead to DNA double-strand break (DSB)
or DNA lesion signaling, and activation of subsequent DNA
repair pathways. Conversely, these cellular processes could also
participate in the resolution of L1 integration, through L1 second
strand DNA synthesis or DNA ligation.
The role of DSB signaling and non-homologous end-joining
(NHEJ) pathways remains controversial. Ataxia-telangiectasia
mutated (ATM) protein, a kinase activated upon DSB, was
initially proposed to be required for L1 retrotransposition and
L1-induced DSBs (Gasior et al., 2006; Wallace et al., 2013).
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However, independent studies using ATM-deficient mice or
human cell models rather suggest that ATM is a repressor
of retrotransposition (Coufal et al., 2011). Similarly, knocking
out NHEJ genes (e.g., Ku70/80, DNA Ligase IV or Artemis)
decreases L1 retrotransposition in chicken cells (Suzuki et al.,
2009). However, loss-of-function of DNA-PKcs or DNA Ligase
IV in mammalian cells does not impair L1 retrotransposition
(Coufal et al., 2011), indicating that NHEJ is not absolutely
required for L1 retrotransposition. An interesting possibility
could be that DSB signaling and repair pathways compete with
the L1 machinery or other cellular factors for the resolution of
L1 insertion during—or after—cDNA synthesis, leading to 5′
truncated insertions (Zingler et al., 2005; Suzuki et al., 2009;
Coufal et al., 2011).
Other DNA repair pathways can also antagonize L1
replication. The ERCC1-XPF complex, which plays a role in
nucleotide excision, base excision and interstrand crosslink
repair pathways is a potent inhibitor of L1 retrotransposition
(Gasior et al., 2008). ERCC1-XPF is an endonuclease able to
specifically cleave DNA at junctions between single-stranded
and double-stranded regions, a predicted structure produced by
the TPRT process. Thus, it has been hypothesized that ERCC1-
XPF might cut off L1 cDNA at the target site during reverse
transcription.
OPEN QUESTIONS FOR THE FUTURE
• How is unspliced L1 RNA exported to the cytosol and the L1
RNP imported back to the nucleus?
• How many distinct L1 RNP forms exist in the cell and
throughout the L1 replication cycle?
• Do L1 components have a life outside of the L1 RNP and
retrotransposition?
• How is L1 RNP assembly regulated?
• Does L1 component accumulation in stress granules reflect
a host defense mechanism or an intermediate step during
retrotransposition?
• Which restriction factors are the dominant ones and do they
cooperate?
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